TY - JOUR
T1 - Costes de la tuberculosis en España
T2 - factores relacionados
AU - Grupo de Trabajo del Programa Integrado de Investigación en Tuberculosis (PII TB)
AU - Gullón, José Antonio
AU - García-García, José María
AU - Villanueva, Manuel Ángel
AU - Álvarez-Navascues, Fernando
AU - Rodrigo, Teresa
AU - Casals, Martí
AU - Anibarro, Luis
AU - García-Clemente, Marta María
AU - Jiménez, María Ángeles
AU - Bustamante, Ana
AU - Penas, Antón
AU - Caminero, José Antonio
AU - Caylà, Joan
N1 - Funding Information:
This project was funded by SEPAR grant 136/2013.
Publisher Copyright:
© 2016 SEPAR
PY - 2016/12/1
Y1 - 2016/12/1
N2 - Objective To analyze the direct and indirect costs of diagnosis and management of tuberculosis (TB) and associated factors. Patients and methods Prospective study of patients diagnosed with TB between September 2014 and September 2015. We calculated direct (hospital stays, visits, diagnostic tests, and treatment) and indirect (sick leave and loss of productivity, contact tracing, and rehabilitation) costs. The following cost-related variables were compared: age, gender, country of origin, hospital stays, diagnostic testing, sensitivity testing, treatment, resistance, directed observed therapy (DOT), and days of sick leave. Proportions were compared using the chi-squared test and significant variables were included in a logistic regression analysis to calculate odds ratio (OR) and corresponding 95% confidence intervals. Results 319 patients were included with a mean age of 56.72 ± 20.79 years. The average cost was €10,262.62 ± 14,961.66, which increased significantly when associated with hospital admission, polymerase chain reaction, sputum smears and cultures, sensitvity testing, chest computed tomography, pleural biopsy, drug treatment longer than nine months, DOT and sick leave. In the multivariate analysis, hospitalization (OR = 96.8; CI 29-472), sensitivity testing (OR = 4.34; CI 1.71-12.1), chest CT (OR= 2.25; CI 1.08-4.77), DOT (OR = 20.76; CI 4.11-148) and sick leave (OR = 26,9; CI 8,51-122) showed an independent association with cost. Conclusion Tuberculosis gives rise to significant health spending. In order to reduce these costs, more control of transmission, and fewer hospital admissions would be required.
AB - Objective To analyze the direct and indirect costs of diagnosis and management of tuberculosis (TB) and associated factors. Patients and methods Prospective study of patients diagnosed with TB between September 2014 and September 2015. We calculated direct (hospital stays, visits, diagnostic tests, and treatment) and indirect (sick leave and loss of productivity, contact tracing, and rehabilitation) costs. The following cost-related variables were compared: age, gender, country of origin, hospital stays, diagnostic testing, sensitivity testing, treatment, resistance, directed observed therapy (DOT), and days of sick leave. Proportions were compared using the chi-squared test and significant variables were included in a logistic regression analysis to calculate odds ratio (OR) and corresponding 95% confidence intervals. Results 319 patients were included with a mean age of 56.72 ± 20.79 years. The average cost was €10,262.62 ± 14,961.66, which increased significantly when associated with hospital admission, polymerase chain reaction, sputum smears and cultures, sensitvity testing, chest computed tomography, pleural biopsy, drug treatment longer than nine months, DOT and sick leave. In the multivariate analysis, hospitalization (OR = 96.8; CI 29-472), sensitivity testing (OR = 4.34; CI 1.71-12.1), chest CT (OR= 2.25; CI 1.08-4.77), DOT (OR = 20.76; CI 4.11-148) and sick leave (OR = 26,9; CI 8,51-122) showed an independent association with cost. Conclusion Tuberculosis gives rise to significant health spending. In order to reduce these costs, more control of transmission, and fewer hospital admissions would be required.
KW - Cost analysis
KW - Hospital income
KW - Tuberculosis
UR - http://www.scopus.com/inward/record.url?scp=85027225379&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85027225379&partnerID=8YFLogxK
U2 - 10.1016/j.arbr.2016.05.015
DO - 10.1016/j.arbr.2016.05.015
M3 - Article
AN - SCOPUS:85027225379
SN - 0300-2896
VL - 52
SP - 583
EP - 589
JO - Archivos de Bronconeumologia
JF - Archivos de Bronconeumologia
IS - 12
ER -